Valeant Pharmaceuticals announced that it will acquire Synergetics USA for $6.50 per share in cash, according to a Valeant press release.“The addition of Synergetics’ portfolio of instruments and devices will further enhance Bausch + Lomb’s presence around the world in the rapidly evolving field of vitreoretinal surgery,” J. Michael Pearson, chairman and CEO of Valeant, said in the release. “We are committed to delivering a valuable and broad array of surgical devices and instruments to serve the needs of the surgical retina community and their patients.”

Full Story →

Valeant Pharmaceuticals announced that it will acquire Synergetics USA for $6.50 per share in cash, according to a Valeant press release.“The addition of Synergetics’ portfolio of instruments and devices will further enhance Bausch + Lomb’s presence around the world in the rapidly evolving field of vitreoretinal surgery,” J. Michael Pearson, chairman and CEO of Valeant, said in the release. “We are committed to delivering a valuable and broad array of surgical devices and instruments to serve the needs of the surgical retina community and their patients.”

Full Story →